Experimental cell therapy targets Tough-to-Treat blood cancer
NCT ID NCT05909527
Summary
This study aimed to test the safety and early effectiveness of an experimental cell therapy called CD7 CAR-T for people with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. The therapy involved collecting a patient's own immune cells, modifying them in a lab to target cancer, and then infusing them back. The trial was designed for children and adults aged 2 to 60, but it was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hebei Yanda Hospital
Langfang, Hebei, 065000, China
Conditions
Explore the condition pages connected to this study.